Cancer is the second leading cause of death worldwide responsible for about 10 million
deaths per year. To date several approaches have been developed to treat this deadly …

Tissue factor (TF) plays an important role in the progression and angiogenesis of tumor
cells. The present study investigated the mechanism of interleukin-1β (IL-1β)-induced TF …

Afatinib, a second-generation, irreversible pan-HER inhibitor, shows better suppression of
T790M-positive lung cancer cells than gefitinib in preclinical studies. However, whether the …

New quinolines substituted with various heterocycles and chalcone moieties were
synthesized and evaluated as antitumor agents. All the synthesized compounds were in vitro …

Objective. To assess the use of cytotoxic drugs as first‐line chemotherapy for nonsquamous
non‐small‐cell lung cancer (NSCLC) with EGFR mutation. Method. This study uses the …

Compared with single-targeted therapy, the design and synthesis of heterozygous
molecules is still a significant challenge for the discovery of antitumor drugs. Quinone …

In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based
for clinical use. These drugs have improved the precision of treatment and reduced adverse …

Background Tumor suppressor CYLD dysfunction by loss of its expression, triggers
malignant transformation, especially drug resistance and tumor invasion/metastasis …

Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility. Inadequate
understanding of the ovulation drivers hinders PCOS intervention. Herein, we report that …

Methods A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …